Liminatus Pharma Inc
LIMNHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET
2.94+0.17 (6.14%)
2026-11-12 05:41 CET
Market cap
3.95 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-12.52 USD m
Free cash flow, TTM
-3.99 USD m
EPS diluted, TTM
-21.48
P/E
-
Price
LIMN against its 20, 50 and 200-day averages2050200
97.9% under the 52-week high of 141.50 on 9 Feb 2026. 52-week low 2.40 on 3 Nov 2026. Last 15 sessions, 35.0% high to low
Volume 0.13× normal · the line is the 50-bar volume average
Profile
LIMN52-week range, 0% of the way up
2.40141.5
Liminatus Pharma, Inc. is a pre-clinical stage biopharmaceutical company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in Cerritos, CA.
| Employees | 1 |
|---|---|
| IPO | May 26, 2021 |
| Beta | 0.77 |
| ATR, 14d | 0.33 |
| Rel volume | 0.13 |
| Short float | 6.14% |
| Insider own | 41.73% |
| Inst own | 4.30% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | 3.95M |
| Enterprise Value | 2.37M |
| Income | -12.52M |
| Sales | 0.00M |
| Book/sh | 0.27 |
| Cash/sh | 2.25 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 1 |
| IPO | May 26, 2021 |
Ratios
| P/E | - |
|---|---|
| Forward P/E | - |
| PEG | - |
| P/S | - |
| P/B | 10.95 |
| P/C | 1.31 |
| P/FCF | - |
| EV/EBITDA | - |
| EV/Sales | - |
| Quick Ratio | 1.12 |
| Current Ratio | 1.12 |
| Debt/Eq | 4.80 |
| LT Debt/Eq | 0.00 |
| Option/Short | No / Yes |
Earnings
| EPS (ttm) | -21.48 |
|---|---|
| EPS next Y | - |
| EPS next Q | - |
| EPS this Y | - |
| EPS next Y | - |
| EPS next 5Y | - |
| EPS past 3/5Y | - -540.05% |
| Sales past 3/5Y | - - |
| EPS Y/Y TTM | -107.04% |
| Sales Y/Y TTM | - |
| EPS Q/Q | -698.35% |
| Sales Q/Q | - |
| Earnings | - |
| EPS/Sales Surpr. | - - |
Ownership
| Insider Own | 41.73% |
|---|---|
| Insider Trans | 0.00% |
| Inst Own | 4.30% |
| Inst Trans | 8.50% |
| ROA | -471.47% |
| ROE | - |
| ROIC | -4165.92% |
| Gross Margin | - |
| Oper. Margin | - |
| Profit Margin | - |
| SMA20 | 1.15% |
| SMA50 | -13.33% |
| SMA200 | -69.79% |
| Trades | - |
Technical
| Shs Outstand | 1.12M |
|---|---|
| Shs Float | 0.78M |
| Short Float | 6.14% |
| Short Ratio | 0.23 |
| Short Interest | 0.05M |
| 52W High | 141.50 -97.92% |
| 52W Low | 2.40 22.32% |
| Volatility | 12.20% 10.47% |
| ATR (14) | 0.33 |
| RSI (14) | 46.23 |
| Beta | 0.77 |
| Rel Volume | 0.13 |
| Avg Volume | 210.43K |
| Volume | 27,654 |
Performance
| Perf Week | 5.21% |
|---|---|
| Perf Month | -13.78% |
| Perf Quarter | -60.77% |
| Perf Half Y | -68.22% |
| Perf YTD | -90.36% |
| Perf Year | -94.95% |
| Perf 3Y | -99.43% |
| Perf 5Y | -99.40% |
| Perf 10Y | - |
| Recom | - |
| Target Price | - |
| Prev Close | 2.77 |
| Price | 2.94 |
| Change % | 6.14% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| ALXO | Alx Oncology Holdings Inc | 154.87M |
| APVO | Aptevo Therapeutics Inc | 1.38M |
| KAPA | Kairos Pharma Ltd | 1.72M |
| HCWB | HCW Biologics Inc | 1.92M |
| IMMP | Immutep Limited ADR | 26.24M |
| PPBT | Purple Biotech Ltd ADR | 2.41M |
| CMPX | Compass Therapeutics Inc | 149.51M |
| ADAG | Adagene Inc ADR | 143.01M |
| CUE | Cue Biopharma Inc | 135.55M |
| XBIT | XBiotech Inc | 59.45M |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VXF | Vanguard Extended Market Index ETF | AUM: 30.47B |
News
latest 14 of 18- Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule (GlobeNewswire) -8.43%
- Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy (GlobeNewswire) -9.50%
- Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock (GlobeNewswire) -8.06% -14.08%
- Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement (GlobeNewswire) +38.16%
- Why is Cathie Wood's ARK Fund Backing this Israeli Innovator? (NASDAQ: MDWD) (FinanceWire) +29.00%
- Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline (GlobeNewswire)
- Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds (GlobeNewswire) -22.21%
- Liminatus Pharma Announces Nasdaq Delisting Notification (GlobeNewswire) +30.99% -31.14%
- BC-Most Active Stocks (Associated Press)
- Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody (GlobeNewswire)
- Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering (GlobeNewswire) -31.86%
- Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation (GlobeNewswire)
- BC-Most Active Stocks (Associated Press Finance) +22.66%
- BNB Falls Below $750 as Crypto Market Sell-Off Erases Corporate-Fueled Optimism (CoinDesk)
Quarterly earnings
actual against estimate| Period | Reported | EPS act | EPS est | EPS rep | Sales act | Sales est | Analysts |
|---|---|---|---|---|---|---|---|
| No quarterly earnings. | |||||||
Annual earnings
| Period | EPS act | EPS est | EPS rep | Sales act | Sales est |
|---|---|---|---|---|---|
| No annual earnings. | |||||
Estimate revisions
last 14 periods| Period | Type | Date | Estimates | Up | Down | Mean | Low | High |
|---|---|---|---|---|---|---|---|---|
| No estimate revisions. | ||||||||
Estimate history
| EPS, annual | -0.002 | 6.333 | 14.885 | -7.652 | -10.133 | -21.484 | -21.4815 | ||
|---|---|---|---|---|---|---|---|---|---|
| Period | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
| EPS, quarterly | -3.721 | -4.481 | -6.137 | -0.001 | 0.243 | -3.376 | -15.092 | -1.561 | -1.454 |
| Period | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
| Sales, annual | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Period | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
| Sales, quarterly | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
| Shares, annual | 0.69 | 0.69 | 0.166 | 0.146 | 0.35 | 0.541 | 1.119 | ||
| Period | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | MRQ | ||
| Shares, quarterly | 0.144 | 0.143 | 0.141 | 0.52 | 0.52 | 0.541 | 0.541 | 0.898 | 1.119 |
| Period | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
Income statement, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY |
|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling, General and Administrative Excl. Other | 4.06 | 2.97 | 3.33 | 2.59 | 2.45 | 2.53 | - |
| Research and Development | 1.00 | 0.00 | 2.69 | - | - | - | - |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -4.07 | -2.97 | -3.33 | -2.59 | -2.45 | -2.53 | 0.00 |
| Interest Expense | 0.08 | 0.22 | 0.34 | 0.10 | - | - | 0.00 |
| Unusual Expense | 8.39 | 7.10 | 0.00 | -0.94 | -10.17 | -6.89 | 0.00 |
| Net Income Before Taxes | -12.52 | -10.21 | -3.55 | -1.19 | 10.79 | 4.37 | -0.00 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.03 | 0.54 | 0.00 | 0.00 |
| Consolidated Net Income | -12.52 | -10.21 | -3.55 | -1.23 | 10.25 | 4.37 | -0.00 |
| Net Income From Continuing Operations | -12.52 | -10.21 | -3.55 | -1.23 | 10.25 | 4.37 | -0.00 |
| Net Income | -12.52 | -10.21 | -3.55 | -1.23 | 10.25 | 4.37 | -0.00 |
| EPS (Recurring) | -6.87 | -11.02 | -10.13 | -11.77 | 4.55 | -0.65 | -0.00 |
| EPS (Basic, Before Extraordinaries) | -21.48 | -21.48 | -10.13 | -7.65 | 14.88 | 6.33 | -0.00 |
| EPS (Diluted) | -21.48 | -21.48 | -10.13 | -7.65 | 14.88 | 6.33 | -0.00 |
| EBITDA | -4.06 | -2.97 | -3.33 | -2.59 | -2.45 | -2.53 | 0.00 |
| Non-Operating Income (Expense) | 0.01 | 0.08 | 0.12 | 0.55 | 3.07 | 0.02 | -0.00 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Shares Outstanding | 1.12 | 0.54 | 0.35 | 0.15 | 0.17 | 0.69 | 0.69 |
| Market Capitalization | 3.95 | 3.95 | 17.43 | - | - | - | - |
Income statement, quarterly
| Metric | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 | 2024Q3 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 | 0.00 | 0.00 |
| Selling, General and Administrative Excl. Other | 1.38 | 1.10 | 0.88 | 0.70 | 1.12 | - | 0.52 | 1.02 |
| Research and Development | 0.60 | 0.40 | 0.00 | 0.00 | 0.00 | - | - | - |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -1.38 | -1.10 | -0.88 | -0.70 | -1.12 | -0.00 | -0.52 | -1.02 |
| Interest Expense | 0.02 | 0.02 | 0.02 | 0.02 | 0.06 | 0.00 | 0.14 | - |
| Unusual Expense | 0.02 | 0.00 | 7.27 | 1.10 | -1.27 | 0.00 | 0.23 | -0.35 |
| Net Income Before Taxes | -1.41 | -1.12 | -8.17 | -1.82 | 0.11 | -0.00 | -0.87 | -0.64 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Consolidated Net Income | -1.41 | -1.12 | -8.17 | -1.82 | 0.11 | -0.00 | -0.87 | -0.64 |
| Net Income From Continuing Operations | -1.41 | -1.12 | -8.17 | -1.82 | 0.11 | -0.00 | -0.87 | -0.64 |
| Net Income | -1.41 | -1.12 | -8.17 | -1.82 | 0.11 | -0.00 | -0.87 | -0.64 |
| EPS (Recurring) | -1.44 | -1.56 | -5.70 | -1.95 | -1.66 | -0.00 | -5.00 | -6.18 |
| EPS (Basic, Before Extraordinaries) | -1.45 | -1.56 | -15.09 | -3.38 | 0.24 | -0.00 | -6.14 | -4.48 |
| EPS (Diluted) | -1.45 | -1.56 | -15.09 | -3.38 | 0.24 | -0.00 | -6.14 | -4.48 |
| EBITDA | -1.38 | -1.10 | -0.88 | -0.70 | -1.12 | -0.00 | -0.52 | -1.02 |
| Non-Operating Income (Expense) | 0.01 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.02 | 0.03 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Shares Outstanding | 1.12 | 0.90 | 0.54 | 0.54 | 0.52 | 0.52 | 0.14 | 0.14 |
| Market Capitalization | 3.95 | 7.71 | 16.51 | 45.20 | 290.06 | 246.62 | - | - |
Balance sheet, annual
| Metric | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 0.34 | 0.06 | 0.16 | 0.28 | 0.34 | 0.00 |
| Short Term Receivables | 0.00 | 3.67 | 0.05 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.16 | 0.16 | 0.00 | 0.08 | 0.08 | 0.00 |
| Total Current Assets | 0.50 | 3.88 | 0.21 | 0.36 | 0.42 | 0.00 |
| Net Property, Plant & Equipment | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Investments and Advances | 0.00 | 0.00 | 4.29 | 15.13 | 276.02 | 0.00 |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.00 | 1.53 | 0.00 | 0.00 | 0.00 | 0.30 |
| Total Assets | 0.51 | 5.41 | 4.50 | 15.49 | 276.44 | 0.30 |
| Short Term Debt Incl. Current Port. of LT Debt | 1.44 | 19.97 | 2.27 | 1.04 | 0.09 | 0.00 |
| Accounts Payable | 0.58 | 1.48 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Tax Payable | - | 0.00 | 0.38 | 0.54 | - | - |
| Other Current Liabilities | 8.27 | 3.29 | 2.51 | 2.01 | 1.29 | 0.28 |
| Total Current Liabilities | 10.30 | 24.75 | 5.16 | 3.59 | 1.38 | 0.28 |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.03 | 0.00 | 10.04 | 10.60 | 20.19 | 0.00 |
| Total Liabilities | 10.33 | 24.75 | 15.19 | 14.19 | 21.57 | 0.28 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | -9.81 | -19.34 | -10.69 | 1.29 | 254.87 | 0.02 |
| Total Shareholders Equity | -9.81 | -19.34 | -10.69 | 1.29 | 254.87 | 0.02 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | -9.81 | -19.34 | -10.69 | 1.29 | 254.87 | 0.02 |
| Total Liabilities & Stockholders Equity | 0.51 | 5.41 | 4.50 | 15.49 | 276.44 | 0.30 |
| Book Value Per Share | -18.13 | -55.26 | -73.17 | 7.78 | 369.38 | 0.03 |
| Tangible Book Value Per Share | -18.13 | -55.26 | -73.17 | 7.78 | 369.38 | 0.03 |
| Full-Time Employees | 1 | 3 | 3 | 3 | - | - |
| Price to Book Ratio | 10.95 | -10.59 | - | - | - | - |
| Return on Assets | -610.85 | -71.56 | -12.27 | 7.02 | 3.16 | - |
| Return on Equity | - | - | - | 8.00 | 3.43 | - |
| Return on Invested Capital | - | - | - | 791.93 | 1.71 | -5.49 |
| Quick Ratio | 0.05 | 0.16 | 0.04 | 0.10 | 0.31 | 0.00 |
| Current Ratio | 0.05 | 0.16 | 0.04 | 0.10 | 0.31 | 0.00 |
Cash flow, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY |
|---|---|---|---|---|---|---|---|
| Net Income | -12.52 | -10.21 | -3.55 | -1.23 | 10.25 | 4.37 | -0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | - | - | - | - |
| Other Funds (Non Cash) | 8.52 | 7.23 | 0.00 | -1.39 | -13.24 | -6.90 | 0.00 |
| Funds from Operations | -4.00 | -2.98 | -3.55 | -2.62 | -2.99 | -2.53 | -0.00 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 0.03 | -6.98 | 2.10 | 0.53 | 1.90 | 1.32 | 0.00 |
| Income Taxes Payable | - | - | -0.38 | -0.16 | 0.54 | - | - |
| Cash from Operating Activities | -3.97 | -9.96 | -1.45 | -2.09 | -1.10 | -1.22 | 0.00 |
| Capital Expenditures | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | -0.78 | -2.85 | 11.39 | 263.96 | -276.00 | 0.00 |
| Purchase of Investments | 0.00 | -0.78 | -2.85 | -0.12 | -15.13 | -276.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 11.51 | 279.09 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -0.01 | -0.79 | -2.85 | 11.39 | 263.96 | -276.00 | 0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 3.10 | 7.99 | 0.00 | -10.66 | -263.96 | 283.07 | 0.00 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | -10.66 | -263.96 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 3.10 | 7.99 | 0.00 | 0.00 | 0.00 | 283.07 | 0.00 |
| Proceedsfrom Stock Options | 1.02 | 7.99 | 0.00 | 0.00 | 0.00 | 283.07 | 0.00 |
| Issuance or Reduction of Debt, Net | 0.00 | 3.04 | 3.92 | 1.23 | 1.04 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 2.56 | 0.00 | 0.00 | 0.00 | 0.00 | -5.52 | 0.00 |
| Other Financing Activities Uses | 2.56 | 0.00 | 0.00 | 0.00 | 0.00 | -5.52 | 0.00 |
| Cash from Financing Activities | 5.66 | 11.03 | 3.92 | -9.42 | -262.92 | 277.55 | 0.00 |
| Net Change in Cash | 1.68 | 0.28 | -0.38 | -0.12 | -0.06 | 0.34 | 0.00 |
| Free Cash Flow | -3.99 | -9.98 | -1.45 | -2.09 | -1.10 | -1.22 | 0.00 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 3.02 | 1.91 | 0.34 | 0.72 | 1.34 | 0.00 |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.38 | 0.87 | 0.16 | 0.48 | 0.44 | 0.00 |
| Total Current Assets | 3.39 | 2.78 | 0.50 | 1.20 | 1.78 | 0.00 |
| Net Property, Plant & Equipment | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.00 | 0.00 | 0.00 | - | - | 0.00 |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.13 | 0.13 | 0.00 |
| Total Assets | 3.40 | 2.79 | 0.51 | 1.34 | 1.91 | 1E-05 |
| Short Term Debt Incl. Current Port. of LT Debt | 1.44 | 1.44 | 1.44 | 1.44 | 1.44 | 0.00 |
| Accounts Payable | 0.66 | 0.53 | 0.58 | 0.56 | 0.43 | 0.00 |
| Other Current Liabilities | 0.94 | 0.92 | 8.27 | 0.86 | 8.64 | 0.00 |
| Total Current Liabilities | 3.04 | 2.89 | 10.30 | 2.86 | 10.52 | 0.00 |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.06 | 0.03 | 0.03 | 0.12 | 0.20 | 0.00 |
| Total Liabilities | 3.10 | 2.92 | 10.33 | 2.99 | 10.72 | 0.00 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 0.30 | -0.13 | -9.81 | -1.65 | -8.81 | -0.00 |
| Total Shareholders Equity | 0.30 | -0.13 | -9.81 | -1.65 | -8.81 | -0.00 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 0.30 | -0.13 | -9.81 | -1.65 | -8.81 | -0.00 |
| Total Liabilities & Stockholders Equity | 3.40 | 2.79 | 0.51 | 1.34 | 1.91 | 1E-05 |
| Book Value Per Share | 0.27 | -0.15 | -18.13 | -3.04 | -16.93 | -0.00 |
| Tangible Book Value Per Share | 0.27 | -0.15 | -18.13 | -3.04 | -16.93 | -0.00 |
| Full-Time Employees | - | - | 1 | - | - | - |
| Price to Book Ratio | 10.95 | -58.18 | -1.68 | -27.46 | -32.93 | -234,653.47 |
| Return on Assets | -471.47 | -788.65 | -591.27 | -116.93 | -51.36 | -88.46 |
| Return on Invested Capital | -468.13 | - | - | - | - | - |
| Quick Ratio | 1.12 | 0.96 | 0.05 | 0.42 | 0.17 | 0.00 |
| Current Ratio | 1.12 | 0.96 | 0.05 | 0.42 | 0.17 | 0.00 |
Cash flow, quarterly
| Metric | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 |
|---|---|---|---|---|---|---|
| Net Income | -1.41 | -1.12 | -8.17 | -1.82 | -0.21 | -0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | - | - |
| Other Funds (Non Cash) | 0.02 | 0.00 | 7.39 | 1.10 | -1.27 | 0.00 |
| Funds from Operations | -1.39 | -1.12 | -0.78 | -0.72 | -1.48 | -0.00 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 0.42 | -0.90 | 0.39 | 0.12 | -7.49 | 0.00 |
| Cash from Operating Activities | -0.97 | -2.02 | -0.39 | -0.60 | -8.98 | 0.00 |
| Capital Expenditures | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | -0.78 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | -0.78 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 0.00 | 0.00 | 0.00 | -0.01 | -0.78 | 0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 2.08 | 3.59 | 0.00 | -2.56 | 10.56 | 0.00 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 2.08 | 3.59 | 0.00 | -2.56 | 10.56 | 0.00 |
| Proceedsfrom Stock Options | 0.00 | 3.59 | 0.00 | -2.56 | 10.56 | 0.00 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 3.04 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 2.56 | -2.56 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 2.56 | -2.56 | 0.00 |
| Cash from Financing Activities | 2.08 | 3.59 | 0.00 | 0.00 | 11.03 | 0.00 |
| Net Change in Cash | 1.11 | 1.57 | -0.39 | -0.61 | - | - |
| Free Cash Flow | -0.97 | -2.02 | -0.39 | -0.61 | -8.98 | 0.00 |
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 6.14% | 0.0M | 0.8M | 220.14K |
| 2026-10-15 | 5.08% | 0.0M | 0.8M | 411.98K |
| 2026-09-30 | 5.71% | 0.0M | 0.8M | 653.59K |
| 2026-09-15 | 7.54% | 0.1M | 0.8M | 684.23K |
| 2026-08-31 | 12.24% | 0.1M | 0.8M | 683.02K |
| 2026-08-14 | 0.53% | 0.2M | 39.1M | 809.71K |
| 2026-07-31 | 10.82% | 0.1M | 0.8M | 616.35K |
| 2026-07-15 | 6.14% | 0.0M | 0.8M | 427.94K |
| 2026-06-30 | 4.43% | 0.0M | 0.5M | 223.15K |
| 2026-06-15 | 3.90% | 0.0M | 0.5M | 200.28K |
| 2026-05-29 | 5.26% | 0.0M | 0.5M | 194.63K |
| 2026-05-15 | 2.41% | 0.0M | 0.5M | 88.72K |
| 2026-04-30 | 5.33% | 0.0M | 0.4M | 228.51K |
| 2026-04-15 | 9.78% | 0.0M | 0.4M | 222.92K |
| 2026-03-31 | 7.66% | 0.0M | 0.2M | 177.87K |
| 2026-03-13 | 12.33% | 0.0M | 0.2M | 172.69K |
| 2026-02-27 | 16.20% | 0.0M | 0.2M | 165.09K |
| 2026-02-13 | 33.18% | 0.1M | 0.2M | 143.86K |
| 2026-01-30 | 1.08% | 0.0M | 0.1M | 3.83K |
| 2026-01-15 | 1.22% | 0.0M | 0.1M | 5.44K |
Option chain
expiry 2026-11-11| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| No option chain for this symbol. | ||||||||||
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-03 | 8-K | Current report | 2026-11-02 | SEC |
| 2026-09-29 | 8-K | Current report | 2026-09-24 | SEC |
| 2026-08-18 | 8-K | Current report | 2026-08-18 | SEC |
| 2026-08-14 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-04 | 8-K | Current report | 2026-08-03 | SEC |
| 2026-07-30 | 8-K | Current report | 2026-07-29 | SEC |
| 2026-07-24 | 8-K | Current report | 2026-07-20 | SEC |
| 2026-07-22 | SCHEDULE 13G | SEC | ||
| 2026-07-14 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-02 | SEC |
| 2026-07-14 | SCHEDULE 13D/A | SEC | ||
| 2026-07-13 | DEF 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-08-03 | SEC |
| 2026-07-06 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-24 | SEC |
| 2026-07-06 | 3 | Initial statement of beneficial ownership of securities | 2026-06-24 | SEC |
| 2026-07-06 | SCHEDULE 13G/A | SEC | ||
| 2026-07-06 | 8-K | Current report | 2026-06-29 | SEC |
| 2026-06-30 | PRE 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-06-29 | SEC |
| 2026-06-24 | S-1 | General form of registration statement for all companies including face-amount certificate companies | SEC | |
| 2026-06-18 | D | Notice of sales of securities on Form D (Regulation D) | SEC | |
| 2026-06-03 | 8-K | Current report | 2026-06-03 | SEC |
| 2026-06-03 | 424B3 | SEC | ||
| 2026-05-27 | 8-K | Current report | 2026-05-20 | SEC |
| 2026-05-20 | 8-K | Current report | 2026-05-17 | SEC |
| 2026-05-15 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-03-31 | SEC |
| 2026-03-31 | 10-K | Annual report pursuant to Section 13 or 15(d) | 2025-12-31 | SEC |
| 2026-03-04 | 8-K | Current report | 2026-02-27 | SEC |
| 2026-02-20 | SCHEDULE 13G | SEC | ||
| 2026-02-18 | 8-K | Current report | 2026-02-17 | SEC |
| 2026-02-18 | 424B4 | SEC | ||
| 2026-02-13 | EFFECT | Effectiveness filing by commission order | SEC | |
| 2026-02-11 | CORRESP | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 3.07% |
| Cygnus Capital Advisors, LLC | 0.73% |
| XTX Topco Ltd | 0.49% |
| CITADEL ADVISORS LLC | 0.12% |
| VANGUARD CAPITAL MANAGEMENT LLC | 0.11% |
| GOLDMAN SACHS GROUP INC | 0.09% |
| UBS Group AG | 0.09% |
| StoneX Group Inc. | 0.06% |
| VANGUARD FIDUCIARY TRUST CO | 0.05% |
| STATE STREET CORP | 0.04% |
Funds
| Fund | % owned |
|---|---|
| Fidelity Nasdaq Composite Index Fund | 2.96% |
| Fidelity Extended Market Index Fund | 0.18% |
| VANGUARD EXTENDED MARKET INDEX FUND | 0.11% |
| Fidelity Total Market Index Fund | 0.01% |
| Fidelity Series Total Market Index Fund | 0.01% |
OakChart. LIMN. Cached 15 minutes.
Some panels did not load: ratings, insider.